<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201201278830N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2016-10-22</date_registration>
      <primary_sponsor>Research Affairs, Tehran University of Medical Science</primary_sponsor>
      <public_title>Effects of erythropoietin in palatal wound healing, Effect of Erythropoietin on healing of gingival graft</public_title>
      <acronym></acronym>
      <scientific_title>The Eeffect of Topical Erythropoietin on Palatal Wound Healing Subsequent to Free Gingival Graft in patients with insufficient keratinized gingiva.                          Evaluation of Topical Erythropoietin Application on the Healing Outcome of Gingival Graft Recipient Site; A Randomized Controlled Clinical Trial.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/9316</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Balanced block randomization was used to allocate each patient into one of the following categories:
-	Right side surgery first, treated with distilled water on recipient site and gel without EPO on donor site
-	Right side surgery first, treated with EPO on recipient site and gel containing  EPO on donor site
-	Left side surgery first, treated with distilled water on recipient site and gel without EPO on donor site
-	Left side surgery first, treated with EPO on recipient site and gel containing EPO on donor site, Blinding description: The patient, the surgeon, the initial and final examiner, and the data analyzer are blinded to the intervention. To meet the assumptions of randomization, a number of sealed non-transparent coded envelopes are prepared with letters A, B, C, or D printed on them.  A third individual opens each envelope and explains the sequence of surgery and gel application to the surgeon.</study_design>
      <phase>1-2</phase>
      <hc_freetext>palatal wound.</hc_freetext>
      <i_freetext>Intervention 1: Control group:A 10*15 mm template is used to harvest a graft from premolar and first molar area of the hard palate and is fixed in the recipient site.In control site: After bleeding control in the donor site, the day of surgery and 2 days after surgery 1ml of the hydroxy ethyl cellulose without Erythropoietin is applied on the wound site.To prepare the bed, a split thickness horizontal incision at mucogingival junction (15 mm long) and two vertical incisions at both ends (10 mm long) is made with scalpel blade no. 15. The control sides receive 1 ml of distilled water. After two minutes, the harvested gingival graft is adapted on the site and stabilized with synthetic absorbable 4/0 sutures (Polyglycolate coated; SUPABON, SUPA, Iran). Then the wound sites are  covered with a foil and the periodontal pack (coe pak, GC America Co., USA). Intervention 2: Intervention group: A 10*15 mm template is used to harvest a graft from premolar and first molar area of the hard palate and is fixed in the recipient site.After bleeding control in the donor site, the day of surgery and 2 days after surgery 1ml of the hydroxy ethyl cellulose gel containing 4,000 IU ml-1Erythropoietin (pooyesh daroo) is  applied on the wound site.Then the wound sites are  covered with a foil and the periodontal pack (coe pak, GC America) is placed over them.                                               To prepare the bed, a split thickness horizontal incision at mucogingival junction (15 mm long) and two vertical incisions at both ends (10 mm long) is made with scalpel blade no. 15. Test sides are treated with 1 ml erythropoietin (EPO) 4000 IU ( PDpoetin, Pooyeshdarou, Tehran, Iran) . After two minutes, the harvested gingival graft is adapted on the site and stabilized with synthetic absorbable 4/0 sutures (Polyglycolate coated; SUPABON, SUPA, Iran). Then the wound sites are  covered with a foil and the periodontal pack (coe pak, GC America Co., USA).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is According to the routine process of publications, the data will be presented to the journal if required or every researcher who asks for.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Siamak Yaghobee</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Amirabad 14399-55991</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1439955991</zip>
        <telephone>+98 21 8835 1168</telephone>
        <email>ninarouzmeh@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>SeyedehNina Rouzmeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Amirabad Street, Post code: 14399-55991, Tehran, Iran,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۳۹۹۵۵۹۹۱</zip>
        <telephone>+98 21 8835 1168</telephone>
        <email>ninarouzmeh@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>age of 18 years old or above
periodontal health;
need for gingival graft in order to augment keratinized gingiva in at least two mandibular areas</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group:A 10*15 mm template is used to harvest a graft from premolar and first molar area of the hard palate and is fixed in the recipient site.In control site: After bleeding control in the donor site, the day of surgery and 2 days after surgery 1ml of the hydroxy ethyl cellulose without Erythropoietin is applied on the wound site.To prepare the bed, a split thickness horizontal incision at mucogingival junction (15 mm long) and two vertical incisions at both ends (10 mm long) is made with scalpel blade no. 15. The control sides receive 1 ml of distilled water. After two minutes, the harvested gingival graft is adapted on the site and stabilized with synthetic absorbable 4/0 sutures (Polyglycolate coated; SUPABON, SUPA, Iran). Then the wound sites are  covered with a foil and the periodontal pack (coe pak, GC America Co., USA).</i_keyword>
      <i_keyword>Intervention group: A 10*15 mm template is used to harvest a graft from premolar and first molar area of the hard palate and is fixed in the recipient site.After bleeding control in the donor site, the day of surgery and 2 days after surgery 1ml of the hydroxy ethyl cellulose gel containing 4,000 IU ml-1Erythropoietin (pooyesh daroo) is  applied on the wound site.Then the wound sites are  covered with a foil and the periodontal pack (coe pak, GC America) is placed over them.                                               To prepare the bed, a split thickness horizontal incision at mucogingival junction (15 mm long) and two vertical incisions at both ends (10 mm long) is made with scalpel blade no. 15. Test sides are treated with 1 ml erythropoietin (EPO) 4000 IU ( PDpoetin, Pooyeshdarou, Tehran, Iran) . After two minutes, the harvested gingival graft is adapted on the site and stabilized with synthetic absorbable 4/0 sutures (Polyglycolate coated; SUPABON, SUPA, Iran). Then the wound sites are  covered with a foil and the periodontal pack (coe pak, GC America Co., USA).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Epithelialization. Timepoint: on days 7, 14 , 21 and 28. Method of measurement: Hydrogen Peroxide 3% application.</prim_outcome>
      <prim_outcome>Degree of healing. Timepoint: on days 7, 14,21,28, 60, 90. Method of measurement: Graft color match, contour, and texture.</prim_outcome>
      <prim_outcome>Inflammation on recipient site. Timepoint: on days 7, 14,21,28, 60, 90. Method of measurement: based on the size of the red inflammatory halo around the graft.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Inflammation. Timepoint: on days 7,14,21 and 28. Method of measurement: direct observation of the region, also photographs taken from test and control areas are prepared to be observed by three periodontists.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research Affairs, Tehran University of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-11-23</approval_date>
        <contact_name>Ethics committe of Tehran University of Medical Science</contact_name>
        <contact_address>North Karegar Street Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
